Abstract
Breast cancer development and progression is regulated by crosstalk between steroid hormones (SHs) (e.g., estrogens, progestins and androgens) and growth factors such as insulin-like growth factors (IGFs), insulin, epidermal growth factors (EGFs), transforming growth factors, and vascular endothelial growth factor. The biological effects of SHs are mediated by the nuclear receptors acting as transcriptional activators. Steroid hormone receptors (SRs), in addition to being induced by their own ligands, are also regulated by cellular kinases activated by growth factors. Growth factors are known to influence the expression and activity of SRs as well as regulate the action of various SR transcriptional cofactors. In turn, the expression of growth factor receptors, their ligands, and signaling molecules is often controlled by SHs. This review will focus on crosstalk between the IGF-I system and several SRs implicated in breast cancer.
Keywords: C-terminal LBD, AF1 (activation function 1), cyclin D1 protein expression, Progestins, Androgens, Src homology 2
Current Pharmaceutical Design
Title: Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Volume: 13 Issue: 7
Author(s): Diego Sisci and Eva Surmacz
Affiliation:
Keywords: C-terminal LBD, AF1 (activation function 1), cyclin D1 protein expression, Progestins, Androgens, Src homology 2
Abstract: Breast cancer development and progression is regulated by crosstalk between steroid hormones (SHs) (e.g., estrogens, progestins and androgens) and growth factors such as insulin-like growth factors (IGFs), insulin, epidermal growth factors (EGFs), transforming growth factors, and vascular endothelial growth factor. The biological effects of SHs are mediated by the nuclear receptors acting as transcriptional activators. Steroid hormone receptors (SRs), in addition to being induced by their own ligands, are also regulated by cellular kinases activated by growth factors. Growth factors are known to influence the expression and activity of SRs as well as regulate the action of various SR transcriptional cofactors. In turn, the expression of growth factor receptors, their ligands, and signaling molecules is often controlled by SHs. This review will focus on crosstalk between the IGF-I system and several SRs implicated in breast cancer.
Export Options
About this article
Cite this article as:
Sisci Diego and Surmacz Eva, Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer, Current Pharmaceutical Design 2007; 13 (7) . https://dx.doi.org/10.2174/138161207780249182
DOI https://dx.doi.org/10.2174/138161207780249182 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multi-Kinase Inhibitors
Current Medicinal Chemistry IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) Medicinal Chemistry of Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery C75, a Fatty Acid Synthase (FAS) Inhibitor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Synthesis, In Vitro Antitumor Activity and Molecular Mechanism of Novel Furan Derivatives and their Precursors
Anti-Cancer Agents in Medicinal Chemistry Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics New Insight into Triple-Negative Breast Cancer Therapy: The Potential Roles of Endoplasmic Reticulum Stress and Autophagy Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Synthesis and In Vitro Biochemical Evaluation of a Series of Compounds as Potential Inhibitors of Estrone Sulfatase (ES) and the Role of pKa in both the Synthesis and the Inhibitory Activity of the Potential Inhibitors
Letters in Drug Design & Discovery Synthetic Lethality-Based Therapeutics: Perspectives for Applications in Colorectal Cancer
Current Cancer Drug Targets Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?
Current Women`s Health Reviews Pharmacogenetics of Obesity Drug Therapy
Current Molecular Medicine Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Use of ‘Omic’ Approaches in Unraveling Mechanisms of Gene-Environment Interactions
Current Genomics FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry